Twinbeech Capital LP Blueprint Medicines Corp Transaction History

Twinbeech Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $1.41 Million - $2.99 Million	32,157 New	32,157 $2.97 Million
Q1 2023 May 15, 2023	BUY	$37.97 - $50.0 $184,116 - $242,450	4,849 New	4,849 $218,000
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $2.17 Million - $3.38 Million	43,535 Added 434.74%	53,549 $3.53 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $452,933 - $702,482	10,014 New	10,014 $506,000
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $486,635 - $675,697	-8,524 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $410,089 - $700,843	8,524 New	8,524 $498,000

362

62.7M

2.24M

1.15M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.18B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.